Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nurix Therapeutics, Inc. - Common stock
(NQ:
NRIX
)
12.94
+0.16 (+1.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nurix Therapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
December 11, 2023
Via
Benzinga
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
October 17, 2023
Via
Benzinga
The Latest Analyst Ratings for Nurix Therapeutics
October 13, 2023
Via
Benzinga
Why Is Cancer Focused Nurix Therapeutics Stock Trading Higher Today?
September 07, 2023
Nurix Therapeutics Inc (NASDAQ: NRIX) has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc (NASDAQ: SGEN) to advance a new class of medicines called...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Nurix Therapeutics
September 07, 2023
Via
Benzinga
Designer Brands, Calavo Growers, Couchbase And Other Big Stocks Moving Higher On Thursday
September 07, 2023
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Analyst Ratings for Nurix Therapeutics
July 24, 2023
Via
Benzinga
Nurix Therapeutics's Return On Capital Employed Insights
July 14, 2023
Via
Benzinga
Analyst Cuts Nurix Therapeutics Price Target By 38%, Cites Lymphoma Data
July 24, 2023
HC Wainwright analyst Robert Burns has lowered the price target for Nurix Therapeutics Inc (NASDAQ: NRIX)
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
July 14, 2023
It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Analyst Ratings for Nurix Therapeutics
April 14, 2023
Via
Benzinga
JPMorgan, Citigroup, QuidelOrtho And Other Big Stocks Moving Higher On Friday
April 14, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Nurix Therapeutics Inc. (NASDAQ: NRIX) Highlighted for Surprising Price Action
April 13, 2023
Via
Investor Brand Network
Expert Ratings for Nurix Therapeutics
March 21, 2023
Via
Benzinga
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics
March 20, 2023
Via
Benzinga
Analyst Ratings for Nurix Therapeutics
February 28, 2023
Via
Benzinga
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
March 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
March 09, 2023
Via
Benzinga
Nurix Therapeutics's Return On Capital Employed Overview
February 14, 2023
Via
Benzinga
Where Nurix Therapeutics Stands With Analysts
July 08, 2022
Within the last quarter, Nurix Therapeutics (NASDAQ:NRIX) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
February 28, 2023
Via
Benzinga
The Top 5 Stocks Cathie Wood Bought and Sold This Week
October 21, 2022
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager.
Via
InvestorPlace
CSX, Veris Residential And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
October 21, 2022
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Cathie Wood Loads Up Over $6.7M In Adobe Stock As It Tumbles 27% In A Month — Also Adds Stake In This Biopharma Company
October 10, 2022
Cathie Wood-led ARK Investment Management bought over 23,000 shares of software maker Adobe Inc (NASDAQ: ADBE) through the
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
September 21, 2022
Gainers
Via
Benzinga
Top Russell 2000 Stocks: Trading Opportunities For Next Week - Sunday, Sept. 11
September 11, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Here is a closer look at some Russell 2000 stock...
Via
Talk Markets
Tesla, Twitter And 76 Biggest Movers From Friday
July 11, 2022
Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board...
Via
Benzinga
Why Nurix Therapeutics Shares Are Rising Today
July 08, 2022
Nurix Therapeutics Inc (NASDAQ: NRIX) shares are trading higher by 13.25% to $17.52 Friday afternoon after the company announced a registered direct offering for total gross proceeds of approximately...
Via
Benzinga
Nurix Therapeutics's Return On Capital Employed Insights
July 08, 2022
Benzinga Pro data, Nurix Therapeutics (NASDAQ:NRIX) reported Q2 sales of $11.43 million. Earnings fell to a loss of $45.40 million, resulting in a 6.74% decrease from last quarter.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.